DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 50006/S-084
NDA 50007/S-025
NDA 50480/S-050
NDA 50533/S-040

SUPPLEMENT APPROVAL

Pfizer, Inc.
Attention: Shai Srulovich
Senior Manager, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Mr. Srulovich:

Please refer to your Supplemental New Drug Applications (sNDA's) dated June 15, 2012, received June 15, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA 50-006/S-084, Vibramycin Monohydrate (doxycycline monohydrate) for Oral Suspension
NDA 50-007/S-025, Vibramycin (doxycycline hyclate) Capsules
NDA 50-480/S-050, Vibramycin Calcium (doxycycline calcium oral suspension) Syrup
NDA 50-533/S-040, Vibra-Tabs (doxycycline hyclate) Film Coated Tablets

We acknowledge receipt of your amendments dated July 6, and September 21, 2012 and April 19, 2013.

These "Prior Approval" supplemental new drug applications provide for changes to the *in vitro* Susceptibility Test Interpretive Criteria and the Quality Control Parameters in the **CLINICAL PHARMACOLOGY** section, **Microbiology** subsection of the package insert.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revision below:

In the **Microbiology** subsection, under **Gram-Negative Bacteria**, the "c" in *Vibrio cholerae* should be lower case.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA

automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796-1203.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
04/29/2013